September 29, 2003
Audience: Endocrinologists, pharmacists and other healthcare providers Novo Nordisk and FDA revised the PRECAUTIONS/Drug Interaction section of the prescribing information to inform healthcare professionals of a drug-drug interaction between repaglinide (PRANDIN), a short-acting insulin secretagogue, and gemfibrozil (Lopid) a lipid-lowering agent used to treat dyslipidemia.
A study that evaluated the co-administration of gemfibrozil with PRANDIN in healthy subjects found a significant increase in repaglinide blood levels. Concomitant use may result in enhanced and prolonged blood glucose-lowering effects of repaglinide. For patients already on PRANDIN and gemfibrozil, blood glucose levels should be monitored and PRANDIN dose adjustment may be needed.
Most important information about Prandin
More information about PRANDIN (Repaglinide):
Sciele Signs Exclusive Agreement with Novo Nordisk to Market Prandin and PrandiMet
To buy PRANDIN (Repaglinide) click HERE: My Family Drugstore
Tags: Conditions & Treatments, Medications, Prandin (Repaglinide), Type 2 Diabetes